Drugs / AZD3514
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01351688 | Aug 2011 → Mar 2013 | prostate cancer | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT01162395 | Aug 2010 → Mar 2013 | prostate cancer | AstraZeneca | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AZD3514 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01162395 ↗ |
| Known as | CS-1443 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2346976 ↗ |
| Modality | Small molecule | — CHEMBL2346976 ↗ |
| Route | Oral | “given AZD3514 orally” NCT01162395 ↗ |
| Target | AR | “Androgen Receptor modulator” CHEMBL2346976 ↗ |